Clinical trial · Interventional
Exosome as the Prognostic and Predictive Biomarker in EBC Patients
Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Using Exosome
NCT05955521CI-TRIAL-00068151active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2-positive Breast Cancer | HER2-Positive Breast Carcinoma | ALIAS | 0.90 |
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| exosome and ctDNA evaluation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CtDNA/Exosome evaluation
- interventionNames
- Procedure: exosome and ctDNA evaluation
Primary outcomes (1)
- measure
- Prognostic biomarker for EBC
- timeFrame
- 60 months
- description
- Positive predictive value of ctDNA/Exosome for BC recurrence
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Early breast cancer * Planned neoadjuvant chemotherapy * Triple negative breast cancer or HER2-positive breast cancer Exclusion Criteria: * Stage IV breast cancer * Hormone receptor positive breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.